Guardant Health, Inc.
GHAPI behind this page
GH FY 2025 request
Playground key active
/api/financials?ticker=GH&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue | 982,021 | 739,016 | +32.9% |
Show Business Segments breakouts |
|||
| Reportable Segment | 982,021 | 739,016 | +32.9% |
Show Geography breakouts |
|||
| Non Us | 58,742 | 41,854 | +40.3% |
| US | 923,279 | 697,162 | +32.4% |
| Cost of Revenue | 349,007 | 289,799 | +20.4% |
| Research & Development | 364,191 | 347,753 | +4.7% |
| Sales & Marketing | 494,661 | 364,935 | +35.5% |
| General & Administrative | 211,410 | 180,123 | +17.4% |
| Total Costs & Expenses | 1,419,269 | 1,182,610 | +20.0% |
| Operating Income | -437,248 | -443,594 | +1.4% |
| Interest Income | 34,095 | 53,691 | -36.5% |
| Interest Expense | -3,897 | -2,581 | -51.0% |
| Other Non-Operating Income (Expense) | -10,490 | -42,605 | +75.4% |
| Income Before Taxes | -417,540 | -435,089 | +4.0% |
| Income Tax Expense (Benefit) | -1,263 | 1,284 | -198.4% |
| Net Income | -416,277 | -436,373 | +4.6% |
Show Business Segments breakouts |
|||
| Reportable Segment | -416,277 | -436,373 | +4.6% |
Show Equity Components breakouts |
|||
| Retained Earnings | -416,277 | -436,373 | +4.6% |
| EPS (Basic) | -3.32 | -3.56 | +6.7% |
| EPS (Diluted) | -3.32 | -3.56 | +6.7% |
| Wtd Avg Shares (Basic) | 125,374 | 122,745 | +2.1% |
| Wtd Avg Shares (Diluted) | 125,374 | 122,745 | +2.1% |
| Revenue | 982,021 | 739,016 | +32.9% |
Show Product Lines breakouts |
|||
| Biopharma and data | 210,132 | 177,579 | +18.3% |
| Licensing and other | 8,562 | 13,486 | -36.5% |
| Oncology | 683,595 | 542,827 | +25.9% |
| Screening | 79,732 | 5,124 | +1456.0% |
| Comprehensive Income | -415,928 | -437,899 | +5.0% |
| Net Income Loss Available To Common Stockholders Basic | -416,277 | -436,373 | +4.6% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 378,203 | 525,540 | -28.0% |
| Available For Sale Securities Debt Securities Current | 823,395 | 314,438 | +161.9% |
| Accounts Receivable | 137,849 | 110,253 | +25.0% |
| Inventory | 85,876 | 71,083 | +20.8% |
| Prepaid Expenses & Other Current Assets | 40,723 | 33,800 | +20.5% |
| Total Current Assets | 1,466,046 | 1,055,114 | +38.9% |
| Restricted Cash Noncurrent | 111,214 | 104,215 | +6.7% |
Show Litigation Case breakouts |
|||
| TwinStrand Biosciences And University Of Washington vs. Guardant Health, Inc. | 107.7 | 103.6 | +4.0% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 145,915 | 136,813 | +6.7% |
| Operating Lease Right-of-Use Assets | 158,849 | 142,265 | +11.7% |
| Goodwill | 77,257 | 3,290 | +2248.2% |
Show Business Acquisition breakouts |
|||
| MetaSight Diagnostics Ltd | 73,967 | — | — |
| Other Non-Current Assets | 28,457 | 37,152 | -23.4% |
| Total Assets | 2,013,659 | 1,485,609 | +35.5% |
| Intangible Assets | 5,090 | 6,760 | -24.7% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Licensing Agreements | 4,985 | 6,091 | -18.2% |
| Noncompete Agreements | 105 | 669 | -84.3% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 25,921 | 6,760 | +283.4% |
| Current Liabilities | |||
| Accounts Payable | 54,442 | 38,551 | +41.2% |
| Accrued Employee Benefits Current | 119,646 | 83,219 | +43.8% |
| Accrued Liabilities | 77,889 | 68,345 | +14.0% |
| Deferred Revenue (Current) | 50,753 | 35,468 | +43.1% |
| Total Current Liabilities | 302,730 | 225,583 | +34.2% |
| Non-Current Liabilities | |||
| Convertible Debt Noncurrent | 1,504,000 | 1,142,547 | +31.6% |
| Operating Lease Liabilities | 178,463 | 164,292 | +8.6% |
| Other Non-Current Liabilities | 127,773 | 92,834 | +37.6% |
| Total Liabilities | 2,112,966 | 1,625,256 | +30.0% |
| Long-Term Debt | 1,504,000 | 1,142,547 | +31.6% |
Show Debt Instrument breakouts |
|||
| Convertible Senior Notes Due 2033 · Convertible Debt | 390,339 | — | — |
| Senior Notes Due 2027 · Convertible Debt | 488,584 | 1,142,547 | -57.2% |
| Senior Notes Due 2031 · Convertible Debt | 625,077 | — | — |
| Contract With Customer Liability Noncurrent | 9 | 6.1 | +47.5% |
| Stockholders' Equity | |||
| Common Stock Value Outstanding | 1 | 1 | 0.0% |
| Additional Paid-In Capital | 2,900,056 | 2,443,788 | +18.7% |
| Accumulated Other Comprehensive Income | -4,852 | -5,201 | +6.7% |
| Retained Earnings | -2,994,512 | -2,578,235 | -16.1% |
| Total Stockholders' Equity | -99,307 | -139,647 | +28.9% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -4,852 | -5,201 | +6.7% |
| Additional Paid In Capital | 2,900,056 | 2,443,788 | +18.7% |
| Common Stock | 1 | 1 | 0.0% |
| Retained Earnings | -2,994,512 | -2,578,235 | -16.1% |
| Total Liabilities & Equity | 2,013,659 | 1,485,609 | +35.5% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 39,736 | 42,387 | -6.3% |
| Non Cash Operating Lease Costs | 33,577 | 31,133 | +7.9% |
| Gains Losses On Extinguishment Of Debt | -13,672 | — | — |
| Stock-Based Compensation | 166,217 | 140,411 | +18.4% |
| Proceeds From Interest Received | 7,677 | — | — |
| Accretion Amortization Of Discounts And Premiums Investments | -5,877 | -6,774 | +13.2% |
| Other Asset Impairment Charges | 18,582 | — | — |
| Other Non-Cash Items | -294 | 5,819 | -105.1% |
| Change in Accounts Receivable | -28,175 | -21,389 | -31.7% |
| Change in Inventory | -14,792 | -9,135 | -61.9% |
| Change in Prepaid & Other Assets | -6,354 | -7,691 | +17.4% |
| Increase Decrease In Other Operating Assets | 212 | -2,375 | +108.9% |
| Increase Decrease In Accounts Payable Accrued And Other Liabilities | 52,749 | -2,820 | +1970.5% |
| Increase Decrease In Operating Lease Liabilities | -37,524 | -36,115 | -3.9% |
| Change in Deferred Revenue | 19,455 | 18,663 | +4.2% |
| Net Cash from Operations | -184,760 | -239,858 | +23.0% |
| Deferred Income Taxes | -1,705 | 287 | -694.1% |
| Investing Activities | |||
| Purchases of Investments | -818,231 | -307,323 | -166.2% |
| Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | 307,323 | 35,000 | +778.1% |
| Payments To Acquire Equity Securities Fv Ni | -9,000 | -7,500 | -20.0% |
| Capital Expenditures | -48,306 | -35,085 | -37.7% |
| Payments To Acquire Businesses Net Of Cash Acquired | -58,988 | — | — |
| Net Cash from Investing | -627,202 | -261,308 | -140.0% |
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | 41,224 | 7,899 | +421.9% |
| Financing Activities | |||
| Proceeds From Stock Plans | 13,585 | 11,719 | +15.9% |
| Proceeds From Stock Options Exercised | 19,223 | 3,119 | +516.3% |
| Tax Withholding for Share Compensation | -30,535 | -15,681 | -94.7% |
| Share Repurchases | -45,010 | — | — |
| Proceeds From Sale Of Treasury Stock | 87,872 | — | — |
| Proceeds From Issuance Of Common Stock | 257,128 | — | — |
| Payments Of Stock Issuance Costs | -17,668 | — | — |
| Proceeds From Convertible Debt | 402,500 | — | — |
| Debt Issuance Costs | -24,588 | — | — |
| Proceeds From Hedge Financing Activities | 5,030 | — | — |
| Proceeds From Payments For Other Financing Activities | 3,596 | -153 | +2450.3% |
| Net Cash from Financing | 671,133 | -996 | +67482.8% |
| Amortization of Financing Costs | 3,243 | 2,581 | +25.6% |
| Supplemental | |||
| Interest Paid | 3,771 | — | — |
| Income Taxes Paid | 869 | 1,007 | -13.7% |
| Unpaid Capital Expenditures | 4,111 | 3,809 | +7.9% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 491 | -1,770 | +127.7% |
| Net Change in Cash | -140,338 | -503,932 | +72.2% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 489,417 | 629,755 | -22.3% |
Values in thousands USD. Source: SEC EDGAR 10-K filing.